This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
このページの翻訳は実験的なもので、現在開発中です。お待ちしております
EPZM 株式概要
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States.
Epizyme, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$1.47 |
| 52週高値 | US$5.80 |
| 52週安値 | US$0.41 |
| ベータ | -0.42 |
| 11ヶ月の変化 | -0.68% |
| 3ヶ月変化 | 182.37% |
| 1年変化 | -72.78% |
| 33年間の変化 | -89.29% |
| 5年間の変化 | -89.54% |
| IPOからの変化 | -93.61% |
最新ニュース
Recent updates
Epizyme GAAP EPS of -$0.21, revenue of $27.5M
Aug 09Epizyme Acquisition By Ipsen: CVR Value
Jul 05Some Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Made A Major Cut To Next Year's Estimates
May 16
Epizyme: Taking Advantage Of Recent Sell-Off
Nov 25Health Check: How Prudently Does Epizyme (NASDAQ:EPZM) Use Debt?
Sep 14Industry Analysts Just Made A Sizeable Upgrade To Their Epizyme, Inc. (NASDAQ:EPZM) Revenue Forecasts
Aug 10Epizyme: Potential Comeback With Tazemetostat After Initial Sales Challenge
Jun 22Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jun 08Epizyme gains as peer Constellation attracts sizable premium from MorphoSys
Jun 02Epizyme, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 07Epizyme, Inc. (NASDAQ:EPZM) Analysts Just Trimmed Their Revenue Forecasts By 41%
Feb 25Is Epizyme (NASDAQ:EPZM) Using Too Much Debt?
Jan 16
Epizyme says Boehringer terminates collaboration agreement
Dec 24Would Shareholders Who Purchased Epizyme's (NASDAQ:EPZM) Stock Year Be Happy With The Share price Today?
Dec 12Epizyme Q3 2020 Earnings Preview
Nov 05株主還元
| EPZM | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -3.3% | -3.0% | 0.9% |
| 1Y | -72.8% | 19.2% | 32.4% |
業界別リターン: EPZM underperformed the US Biotechs industry which returned -23% over the past year.
リターン対市場: EPZM underperformed the US Market which returned -11.7% over the past year.
価格変動
| EPZM volatility | |
|---|---|
| EPZM Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: EPZM's share price has been volatile over the past 3 months.
時間の経過による変動: EPZM's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2007 | 250 | Grant Bogle | www.epizyme.com |
Epizyme, Inc. 基礎のまとめ
| EPZM 基礎統計学 | |
|---|---|
| 時価総額 | US$247.50m |
| 収益（TTM） | -US$207.73m |
| 売上高(TTM) | US$53.01m |
4.7x
P/Sレシオ-1.2x
PER（株価収益率EPZM は割高か？
公正価値と評価分析を参照収益と収入
| EPZM 損益計算書（TTM） | |
|---|---|
| 収益 | US$53.01m |
| 売上原価 | US$10.79m |
| 売上総利益 | US$42.22m |
| その他の費用 | US$249.95m |
| 収益 | -US$207.73m |
直近の収益報告
Jun 30, 2022
次回決算日
該当なし
| 一株当たり利益（EPS） | -1.23 |
| グロス・マージン | 79.64% |
| 純利益率 | -391.88% |
| 有利子負債／自己資本比率 | -1,148.4% |
EPZM の長期的なパフォーマンスは？
過去の実績と比較を見る